[go: up one dir, main page]

ATE349521T1 - Mit cd40 und traf interagierende proteine - Google Patents

Mit cd40 und traf interagierende proteine

Info

Publication number
ATE349521T1
ATE349521T1 AT99922165T AT99922165T ATE349521T1 AT E349521 T1 ATE349521 T1 AT E349521T1 AT 99922165 T AT99922165 T AT 99922165T AT 99922165 T AT99922165 T AT 99922165T AT E349521 T1 ATE349521 T1 AT E349521T1
Authority
AT
Austria
Prior art keywords
traf
met
proteins interacting
kappab
proteins
Prior art date
Application number
AT99922165T
Other languages
English (en)
Inventor
Stefan Maria Christiaan Pype
Jacques Emile Fernand Remacle
Danny Francois Eve Huylebroeck
Original Assignee
Vlaams Interuniv Inst Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniv Inst Biotech filed Critical Vlaams Interuniv Inst Biotech
Application granted granted Critical
Publication of ATE349521T1 publication Critical patent/ATE349521T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99922165T 1998-04-29 1999-04-28 Mit cd40 und traf interagierende proteine ATE349521T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98201392 1998-04-29

Publications (1)

Publication Number Publication Date
ATE349521T1 true ATE349521T1 (de) 2007-01-15

Family

ID=8233659

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99922165T ATE349521T1 (de) 1998-04-29 1999-04-28 Mit cd40 und traf interagierende proteine

Country Status (8)

Country Link
US (2) US6812203B1 (de)
EP (1) EP1073739B1 (de)
JP (1) JP2002512796A (de)
AT (1) ATE349521T1 (de)
AU (1) AU752597B2 (de)
CA (1) CA2327504A1 (de)
DE (1) DE69934580T2 (de)
WO (1) WO1999055859A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2327504A1 (en) 1998-04-29 1999-11-04 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Cd40-interacting and traf-interacting proteins
IL154977A0 (en) * 2000-09-19 2003-10-31 Novimmune Sa Statins (hmg-coa reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
AU2004213839B2 (en) * 2003-02-14 2010-08-12 Beth Israel Deaconess Medical Center, Inc. Predicting graft rejection
ES2957957T3 (es) 2010-10-19 2024-01-30 Op T Llc Péptidos para modular la actividad de linfocitos T y usos de los mismos
TWI502199B (zh) * 2013-05-23 2015-10-01 Univ Nat Central 腫瘤壞死因子受體相關因子7作爲紅斑性狼瘡的生物標記物之用途、偵測人體患有紅斑性狼瘡的方法以及偵測人體患有紅斑性狼瘡的套組
US11793854B2 (en) * 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
EP4135742A2 (de) 2020-04-17 2023-02-22 Op-T Llc Bioaktive peptide und verfahren zur verwendung davon

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265556B1 (en) * 1994-12-02 2001-07-24 The Burnham Institute Nucleic acid encoding CD40 associated proteins
US5705625A (en) * 1994-12-15 1998-01-06 The Johns Hopkins University School Of Medicine Nucleic Acid Encoding novel protein tyrosine kinase
US5577124A (en) 1995-03-09 1996-11-19 Arithmetica, Inc. Multi-purpose high speed cryptographically secure sequence generator based on zeta-one-way functions
US6348567B1 (en) * 1995-12-06 2002-02-19 Cv Molecular Therapeutics Inc. Peptides and their use to ameliorate cell death
DE19610262A1 (de) 1996-03-15 1997-09-18 Bayer Ag Verfahren zur Herstellung Kohlenwasserstoff-getriebener Polyurethan-Hartschaumstoffe
AU2593997A (en) * 1996-03-21 1997-10-10 Trustees Of Columbia University In The City Of New York, The Craf1 (traf-3) isoforms and uses thereof
WO1998034946A1 (en) * 1997-02-12 1998-08-13 Massachusetts Institute Of Technology Daxx, a novel fas-binding protein that activates jnk and apoptosis
JPH1175856A (ja) * 1997-09-17 1999-03-23 Takashi Tsuruo トポイソメラーゼ結合タンパク質
US6379951B1 (en) * 1997-12-24 2002-04-30 Corixa Corporation Compounds for immunotherapy of breast cancer and methods for their use
EP1042360A2 (de) * 1997-12-24 2000-10-11 Corixa Corporation Zusammensetzungen für immunotherapie und diagnose von brustkrebs und verfahren für ihre verwendung
CA2327504A1 (en) 1998-04-29 1999-11-04 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Cd40-interacting and traf-interacting proteins
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins

Also Published As

Publication number Publication date
EP1073739B1 (de) 2006-12-27
AU752597B2 (en) 2002-09-26
US7098322B2 (en) 2006-08-29
WO1999055859A3 (en) 2000-02-17
WO1999055859A2 (en) 1999-11-04
CA2327504A1 (en) 1999-11-04
EP1073739A2 (de) 2001-02-07
AU3931099A (en) 1999-11-16
DE69934580D1 (de) 2007-02-08
US6812203B1 (en) 2004-11-02
DE69934580T2 (de) 2007-10-04
US20050101769A1 (en) 2005-05-12
JP2002512796A (ja) 2002-05-08

Similar Documents

Publication Publication Date Title
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
ATE467425T1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
EP1137658A4 (de) VERFAHREN ZUR MODULATION VON TUMOR NECROSIS FAKTOR -g(a)-INDUZIERTER EXPRESSION VON ZELLADHÄSIONSMOLEKÜLEN
DE60028970D1 (de) An her2 bindende peptidverbindungen
DK0910647T3 (da) Human DNase i hyperaktive varianter
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
DE69535673D1 (de) Mittel zur induktion von apoptosis und zur therapieanwendung
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DK1028744T3 (da) Neuronale anvendelser af BMP-11
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE349521T1 (de) Mit cd40 und traf interagierende proteine
ATE316084T1 (de) Substituierte diazepan
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69912743D1 (de) Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges
DE60037978D1 (de) Interferon ähnliche moleküle, und deren verwendungen
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
DE69309790D1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-Furyl)-3-Derivate und pharmazeutische Präparate davon, zur Behandlung von Kardiovaskulär-Erkrankungen
NO20055309D0 (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties